ICM ADX-2191 injection
ADX-2191-PVRL-001
Phase 3 small_molecule active
Quick answer
ICM ADX-2191 injection for Primary Vitreoretinal Lymphoma is a Phase 3 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aldeyra Therapeutics
- Indication
- Primary Vitreoretinal Lymphoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active